Welcome to our dedicated page for Perspective Therapeutics SEC filings (Ticker: CATX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Perspective Therapeutics, Inc. (CATX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Perspective is a radiopharmaceutical development company focused on 212Pb-based theranostic treatments and imaging for cancer, and its filings offer detail on clinical progress, financial condition, and corporate governance.
Recent Form 8-K reports referenced in the input data include announcements of updated corporate presentations, interim clinical results from the Phase 1/2a trial of [212Pb]VMT-α-NET in SSTR2-positive neuroendocrine tumors, and quarterly financial results with business highlights. Other 8-K filings describe executive leadership changes, such as the appointment of a new Chief Financial Officer and amended and restated employment agreements for senior executives, including change-in-control and severance terms.
Through this page, users can review Perspective’s current and historical 8-Ks and, when available, its periodic reports such as Forms 10-K and 10-Q, which typically contain audited or reviewed financial statements, segment information, and risk factor disclosures. These documents help clarify how the company funds its clinical programs, how it accounts for research and development and general and administrative expenses, and how it describes its radiopharmaceutical platform and manufacturing infrastructure enabled by its proprietary 212Pb generator.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify major clinical updates, financial trends, and governance changes. Real-time ingestion from EDGAR, along with structured access to items such as executive compensation arrangements and other material contracts, supports deeper analysis of CATX’s regulatory and corporate history.
Perspective Therapeutics, Inc. ownership disclosure: Avidity reporting group states shared beneficial ownership of 6,049,999 shares of Common Stock, representing 5.3%.
The filing also shows Avidity Private Master Fund I LP holds 5,849,999 shares ( 5.1%). The report is signed by Michael Gregory on 03/10/2026.
Perspective Therapeutics director Maria E. Martinez received a grant of stock options, giving her the right to buy 50,000 shares. The award, approved by the board as her annual 2026 equity grant, was granted on March 2, 2026 and carries a zero exercise price. The option vests in full on March 2, 2027, as long as she continues serving through that date.
Morich Frank reported acquisition or exercise transactions in this Form 4 filing.
Perspective Therapeutics, Inc. director Frank Morich received a grant of stock options covering 50,000 shares as his annual equity award for 2026. The Board of Directors approved the grant on January 26, 2026, with a grant date of March 2, 2026.
The option vests in full on March 2, 2027, provided Morich continues to serve through that date. Following this grant, he holds 50,000 stock options directly, reflecting a standard equity compensation award rather than an open-market share purchase or sale.
Williamson Robert F III reported acquisition or exercise transactions in this Form 4 filing.
Perspective Therapeutics, Inc. director Robert F. Williamson III reported receiving a grant of stock options representing 50,000 shares on March 2, 2026. The award was approved by the board on January 26, 2026 as his annual equity grant for 2026 and will vest in full on March 2, 2027, provided he continues serving through that date.
HENSON HEIDI reported acquisition or exercise transactions in this Form 4 filing.
Perspective Therapeutics director Heidi Henson was granted a stock option covering 50,000 shares on March 2, 2026. The grant was approved by the board as her annual 2026 equity award. The option vests in full on March 2, 2027, if she continues serving through that date.
Perspective Therapeutics director receives 2026 stock option grant. Director Lori A. Woods was granted a stock option to buy 50,000 shares at an exercise price of
Spoor Johan M. reported acquisition or exercise transactions in this Form 4 filing.
Perspective Therapeutics, Inc. reported that Chief Executive Officer Johan M. Spoor was granted stock options covering 735,000 shares on the March 2, 2026 grant date. The award, approved by the board on January 26, 2026, represents his annual 2026 equity grant. The options vest in 48 substantially equal monthly installments starting one month after the grant date, contingent on his continued service.
Perspective Therapeutics reported that Chief Accounting Officer Jonathan Robert Hunt received a grant of stock options representing the right to buy 90,000 shares, with a grant date of March 2, 2026. These options were approved by the board’s compensation committee as his annual equity award for 2026.
The options have a stated exercise price of $0.0000 per share and vest over four years in 48 substantially equal monthly installments starting one month after the grant date, conditioned on his continued service with the company.
Perspective Therapeutics, Inc. reported that Chief Medical Officer Markus Puhlmann received a grant of stock options covering 150,000 shares on the grant date of March 2, 2026. The options were approved by the compensation committee as his annual equity award for 2026 and have an exercise price of
The option award vests and becomes exercisable over four years in 48 substantially equal monthly installments, starting one month after the grant date, so long as he continues serving the company on each vesting date. This is a routine equity compensation grant rather than an open‑market share purchase or sale.
Morgan Stanley has filed a Schedule 13G reporting a significant ownership stake in Perspective Therapeutics, Inc. common stock. As of 12/31/2025, Morgan Stanley reports beneficial ownership of 4,461,893 shares, representing 6.0% of the company’s common stock.
The firm reports no sole voting or dispositive power, with shared voting power over 3,386,203 shares and shared dispositive power over 3,555,365 shares. Morgan Stanley certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Perspective Therapeutics.